Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...

Altoida’s AI-powered device to indicate Alzheimer’s in adults with mild cognitive dementia was given breakthrough designation by the FDA.

Holidays can be difficult for caregivers who have a loved one with dementia, writes columnist Ray Burow. But celebrating is still possible.

A dual vaccine targeting both amyloid plaques and tangled fibers made up of tau may have potential to treat and prevent Alzheimer’s disease.

Foralumab helped to normalize microglial cell activity - tied to Alzheimer's progression - in the mice, leading to signs of better cognition.

Potential stroke therapy 3K3A-APC, about to enter a Phase 3 trial, may also help protect the brain against Alzheimer's and other dementias.

In a significant decision, the FDA approved Adulhelm (aducanumab) as a first targeted Alzheimer's treatment, and first new therapy since 2003.

"Encouraging results" were reported in eight Alzheimer’s patients with dementia who were treated with the experimental therapy COYA 301.

The FDA informed Acadia of 'deficiencies' in its request for Nuplazid to treat dementia-related psychosis, which preclude it moving ahead.

Treatment with bryostatin was found to slow cognitive decline in adults with advanced Alzheimer's disease in a Phase 2 clinical trial.

BioXcel Therapeutics has launched its pivotal Phase 3 trial program to continue to evaluate BXCL501, its oral experimental candidate.